Investing.com - Corvus Pharmaceuticals (NASDAQ: CRVS) reported first quarter EPS of $-0.130, $0.01 worse than the analyst estimate of $-0.120. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.00.
Corvus Pharmaceuticals's stock price closed at $2.280. It is up 18.750% in the last 3 months and up 221.040% in the last 12 months.
Corvus Pharmaceuticals saw 1 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Corvus Pharmaceuticals's stock price’s past reactions to earnings here.
According to InvestingPro, Corvus Pharmaceuticals's Financial Health score is "good performance".
Check out Corvus Pharmaceuticals's recent earnings performance, and Corvus Pharmaceuticals's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar